Dr. Travis H. Stracker is an Investigator in the Radiation Oncology Branch, NCI. He received his undergraduate degree in Genetics from the University of Georgia in 1996. In 2003, he joined the laboratory of Dr. John Petrini in the Molecular Biology Program at the Sloan-Kettering Institute. There, his research focused on the generation and characterization of mouse models of cancer susceptibility and rare diseases associated with genomic instability. He started his laboratory in the IRB Barcelona Cancer Science Program in 2009, where he continued to study the DNA damage response and its implications in rare diseases, cancer, and cancer therapy. In 2020, he joined the NCI. His research focuses on understanding how cancer cells respond to radiotherapy and other DNA-damaging chemotherapies and how these responses can be modulated for therapeutic gain.
Dr. Travis H. Stracker is an Investigator in the Radiation Oncology Branch, NCI. He received his undergraduate degree in Genetics from the University of Georgia in 1996. In 2003, he joined the laboratory of Dr. John Petrini in the Molecular Biology Program at the Sloan-Kettering Institute. There, his research focused on the generation and characterization of mouse models of cancer susceptibility and rare diseases associated with genomic instability. He started his laboratory in the IRB Barcelona Cancer Science Program in 2009, where he continued to study the DNA damage response and its implications in rare diseases, cancer, and cancer therapy. In 2020, he joined the NCI. His research focuses on understanding how cancer cells respond to radiotherapy and other DNA-damaging chemotherapies and how these responses can be modulated for therapeutic gain.